#China #Shanghai #Cancer Immunotherapy #CAR-T therapy #Oricell Therapeutics

Oricell Therapeutics Secures $70 Million in Financing to Advance Cancer Therapies

On January 12, 2026, Oricell Therapeutics Holdings Limited, recognized as a pioneer in innovative cancer immunotherapy, announced the successful closure of its Series C financing round, raising an impressive $70 million. This funding aims to accelerate the development and expansion of CAR-T cell therapies for solid tumors on a global scale.

The financing round was jointly led by prominent investors, including the Beijing Medical and Health Care Industry Investment Fund and Qiming Venture Partners, alongside contributions from a sovereign wealth fund and other notable investors. The strategic injection of capital will not only bolster Oricell's technological capabilities but also pave the way for potential commercialization of its cutting-edge therapies.

Oricell's robust pipeline features a range of differentiated CAR-T cell therapies, established through three proprietary platforms developed over the last ten years:

• - Ori®Ab: A library for antibody discovery and engineering.
• - Ori®Armoring: Enhancing T-cell persistence and functionality through targeted areas.
• - OnGo (Fast) CMC: A rapid, scalable, and effective manufacturing process.

Notably, Oricell has already produced proof-of-concept clinical data for several CAR-T products. Its flagship program, Ori-C101, is designed for the treatment of advanced hepatocellular carcinoma (HCC) and has successfully completed both Phase I Investigator-Initiated Trials and IND studies. The promising clinical data surrounding Ori-C101 has garnered significant attention and recognition, being showcased at major academic conferences including ASCO 2021 and ASCO 2025. Currently, Ori-C101 is gearing up for its pivotal registrational trial, positioning it to potentially be the first approved CAR-T therapy for HCC worldwide.

In addition to Ori-C101, Oricell's innovative platforms are yielding next-generation CAR-T therapies with innovative designs aimed at tackling multiple targets. The company's groundbreaking secreting CAR-T therapy, OriC902, has demonstrated exceptional efficacy and durability in patients with difficult-to-treat solid tumors. Oricell is also conducting an Investigator-Initiated Trial for its proprietary dual-targeted In Vivo CAR-T therapy, which underscores the company's commitment to pioneering advanced cancer treatment options.

Dr. Helen Yang, Chairwoman and CEO of Oricell Therapeutics, expressed her gratitude to the investors, emphasizing their support in propelling Oricell's mission forward. "We are profoundly grateful for the robust endorsement from our investors. Our goal is to accelerate clinical advancements and continue the research and development of our innovative therapies," she stated. Dr. Yang further highlighted Oricell's ambition to provide effective and affordable cell therapies to cancer patients globally, with a mission that underscores the potential for curative outcomes.

Mr. Peng Ren, Chairman and General Manager of Beijing Medical and Health Care Industry Investment Fund, shared his belief in cell therapy's critical role in combatting solid tumors. He acknowledged the remarkable clinical progress of Oricell's GPC3 CAR-T in treating HCC, indicating his eagerness to support the company's rapid advancement toward global clinical breakthroughs.

Qiming Venture Partners' Managing Partner, Mr. Xubo Hu, reflected on the evolution of Oricell from a promising startup to a formidable technology entity in the field of cell therapy. He expressed admiration for Oricell’s relentless innovation and commitment to developing globally impactful cancer therapies.

About Oricell Therapeutics

Oricell Therapeutics is a clinical-stage biotechnology firm focused on developing next-generation cell therapies, primarily targeting unmet needs in oncology and immunology. With its three proprietary platforms, Oricell is actively advancing a diverse pipeline that addresses both solid tumors and hematologic malignancies. Numerous candidates have exhibited favorable tolerability and encouraging clinical activity in early-phase studies, with data presented at leading global conferences and esteemed academic journals. With a commitment to scientific rigor and patient-focused innovation, Oricell aims to revolutionize cell therapy and bring new hope to patients worldwide. For more information, visit www.oricell.com.